@article { ISI:000357034800003,
	title = {Cell line development for biomanufacturing processes: recent advances and an outlook},
	journal = {Biotechnology Letters},
	volume = {37},
	number = {8},
	year = {2015},
	month = {AUG},
	pages = {1553-1564},
	publisher = {SPRINGER},
	address = {VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS},
	abstract = {<p>At the core of a biomanufacturing process for recombinant proteins is the production cell line. It influences the productivity and product quality. Its characteristics also dictate process development, as the process is optimized to complement the producing cell to achieve the target productivity and quality. Advances in the past decade, from vector design to cell line screening, have greatly expanded our capability to attain producing cell lines with certain desired traits. Increasing availability of genomic and transcriptomic resources for industrially important cell lines coupled with advances in genome editing technology have opened new avenues for cell line development. These developments are poised to help biosimilar manufacturing, which requires targeting pre-defined product quality attributes, e.g., glycoform, to match the innovator{\textquoteright}s range. This review summarizes recent advances and discusses future possibilities in this area.</p>},
	keywords = {Biomanufacturing, Biosimilars, Cell line development, CHO cells genomics, Genome editing, Transcriptomics},
	issn = {0141-5492},
	doi = {10.1007/s10529-015-1843-z},
	author = {Le, Huong and Vishwanathan, Nandita and Jacob, Nitya M. and Gadgil, Mugdha and Hu, Wei-Shou}
}
@article {45718,
	title = {Cell culture processes for biopharmaceutical manufacturing},
	journal = {Current Science},
	volume = {112},
	year = {2017},
	month = {APR },
	pages = {1478-1488},
	type = {Article},
	abstract = {<p>Recombinant proteins manufactured using animal cell culture processes comprise a significant fraction of biopharmaceuticals. With the expiry of patents on this class of therapeutics, there is also a significant interest in manufacture of biosimilar versions of such therapeutics. This article provides a birds-eye view of upstream process development for animal cell culture processes, with a focus on advances pertinent to the development of processes for biosimilars.</p>},
	keywords = {Biopharmaceutical, Cell line development, CHO, glycosylation, monoclonal antibody},
	issn = {0011-3891},
	doi = {10.18520/cs/v112/i07/1478-1488},
	author = {Gadgil, Mugdha}
}
